Farnesyl transferase inhibitors

Details Farnesyl transferase inhibitors Farnesyl transferase inhibitors

2006-04-04

2006-04-04

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

54

Reexamination Certificate

active

07022704

ABSTRACT:
A family of tetrahydroimidazo[1,2a]pyrazine based compounds capable of inhibiting the activity of farnesyl transferase and treating tumors and restenosis having the following structure:or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the specification.

REFERENCES:
patent: 5229386 (1993-07-01), Takasugi et al.
patent: 6673927 (2004-01-01), Gordon et al.
patent: WO94/26723 (1994-11-01), None
patent: WO95/00497 (1995-01-01), None
patent: WO 97/19075 (1997-05-01), None
Cohen et al. Biochemical Pharmacology, vol. 60, pp. 1061-1068 (2000).
Khosravi-Far et al., Cell Growth & Differentiation, vol. 3;461-469.
Shide et al., “Rational—Design of Potent Carboxylic Acid Based Bisubstrate Inhibitors of Ras Farnesyl Protein Transferase”, Bioorganic & Medicinal Chemistry Letters, 4:2107-2112, 1994.
Bishop et al., “Novel Tricyclic Inhibitors of Farnesyl Protein Transferase”, The Journal of Biological Chemistry, 270:30611-30618, 1995.
Buss et al., “Farnesyl Transferase Inhibitors: the Successes and Surprises of a New Class of Potential Cancer Chemotherapeutics”, Chemistry & Biology, 2:787-791, 1995.
Clerc et al., “Constrained Analogs of KCVFM with Improved Inhibitory Properties Against Farnesyl Transferase” Bioorganic & Medicinal Chemistry Letters, 5:1779-1784, 1995.
deSolms et al., “Pseudodipeptide Inhibitors of Protein Farnesyltransferase”, J. Ned. Chem.,38:3967-3971, 1995.
Garcia et al., “Peptidominmetic Inhibitors of Ras Farnesylation and Function in Whole Cells”, The Journal of Biological Chemistry, 268:18415-18418, 1993.
Gibbs et al., “Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutic”, Cell, 77:175-178, 1994.
Graham et al., “Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase”, J. Med. Chem. 37:725-732, 1994.
Harrington et al., “Cysteine and Methionine Linked by Carbon Pseudopeptides Inhibit Farnesyl Transferase”, Bioorganic & Medicinal Chemistry Letters, 4:2775-2780, 1994.
Hunt et al., “Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase”, J. Med. Chem. 39:353-358, 1996.
James et al., “Senzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells”, Science, 260:1937-1942, 1993.
James et al., “Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro”, The Journal of Biological Chem., 270:6221-6226, 1995.
Koblan et al., “NMR Studies of Novel Inhibitors Bound to FarnesyL-Protein Transferase”, Protein Science, 4:681-688, 1995.
Kohl et al., “Development of Inhibitors of Protein Farnesylation as Potential Chemotherapeutic Agents”, Journal of Cellular Biochemistry, 22:145-150, 1995.
Kohl et al., “Inhibition of Farnesyltransferase Induces Regression of Mammary and Salivary Carcinomas in Ras Transgenic Mice”, Nature Medicine, 1:792-797, 1995.
Kohl et al., “Inhibition of Ras Function in Vitro and In Vivo Using Inhibitors of Farnesyl-Protein Transferase”, Methods in Enzymology, 255:378-386, 1995.
Kohl et al., “Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor”, Science, 260:1934-1937, 1993.
Leftheris et al., “Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity”, J. Med. Chem., 39:224-236, 1996.
Lerner et al., “Ras CAAX Peptidomimetic FTI-277 Selectively Block Oncogenic Ras Signaling by Inducing Cytoplastmic Accumulation of Inactive Ras-Raf Complexes”, The J. of Biological Chem., 270:26802-26806, 1995.
Nagasu et al., “Inhibition of Hunan Tumor Xenograft Growth by Treatment with the Farnesyl.Transferase Inhibitor 8956”, Cancer Research, 55:5310-5314, 1995.
Nigam et al., “Potent Inhibition of Human Tumor p21rasFarnesyltransferase by AIAz-Lacking p21rasCA1A2X Peptidomimetics”, The Journal of Biological Chemistry, 268:20695-20698, 1993.
Patel et al., “Phenol Based Tripeptide Inhibitors of Ras Farnesyl Protein Transferase”, Sioorganic & Medicinal Chemistry Letters, 4:1883-1888, 1994.
Wan et al., “Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors”, J. Med. Chem., 39:217-223, 1996.
Oian et al., “Design and Structural Requirements of Potent Peptidomimetic Inhibitors of p21ras Farnesyltransferase”, The Journal of Biological Chemistry, 269:12410-12413, 1994.
Reiss et al., “Sequence Requirement for Peptide Recognition by Rat Brain p21r,sProtein Farnesyltransferase”,I Proc. Matt. Aced. Sci., 88:732-736, 1991.
Sepp-Lorenzino et al., “A Peptidomimetic Inhibitor of Farnesyl: Protein Transferase Blocks the Anchorage Dependent and -Independent Growth of Human Tumor Cell Lines”, Cancer Research, 55:5302-5309, 1995.
Singh et al., “Fusidienot: A Novel Inhibitor of Ras Farnesyl-Protein Transferase from Fusidiua Griseum”, Pergamon Tetrahedron Letters, 35:4693-4696, 1994.
Vogt et al., “A Non-Peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing”, The Journal of Biological Chemistry, 270:660-664, 1995.
Williams et al., “2-Substituted Piperazines as Constrained Amino Acids. Application to the Synthesis of Potent, Non Carboxylic Acid Inhibitors of Farnesyltransferase”, J. Med. Chem., 39:1345-1348, 1996.

Affiliated with

Also associated with

Rating

Farnesyl transferase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Farnesyl transferase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Farnesyl transferase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3555083